Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07136012 · ClinicalTrials.gov registry record · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
A Phase 3 study of Cardiovascular Disease, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 11,000
- Enrollment target
- 20
- Study locations
NCT07136012: Recruiting Phase 3 study of Cardiovascular Disease, sponsored by Amgen.
NCT07136012 is a Phase 3 study of Cardiovascular Disease that is actively recruiting participants, run by Amgen. The registered enrollment target is 11,000 participants, above the 2,617-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (320% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07136012, a Phase 3 study of Cardiovascular Disease, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 11,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Olpasiran
Study Locations (20)
Alabama
- Advanced Cardiovascular LLC - Alexander City
- University of Alabama Birmingham Saint Vincents Birmingham - Birmingham
- Birmingham Clinical Research - Birmingham
- Alliance For Multispecialty Research - Daphne - Daphne
- Eastern Shore Research Institute - Fairhope
- Heart Center Research LLC - Huntsville
- CB Flock Research Corporation - Mobile
California
- National Heart Institute - Beverly Hills
- 310 Clinical Research - Inglewood
- University of California San Diego - La Jolla
- InvivoCure - Los Angeles
- Valley Clinical Trials - Northridge
- Clinical Trials Research - Sacramento - Roseville
- Alliance Clinical Research - San Diego
Arizona
- Phoenix Clinical - Phoenix
- Elite Clinical Studies LLC - Phoenix
- Hero Clinical Research - Phoenix
- HonorHealth Research Institute - Scottsdale
- Eclipse Clinical Research - Tucson
Arkansas
- Lynn Institute of the Ozarks - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,000 participants |
| Start Date | 2025-08-22 |
| Est. Completion | 2031-10-20 |
| Phase | Phase 3 |
What NCT07136012 shows while recruiting
NCT07136012 is an interventional study that assigns participants to a tested intervention. Its 11,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,617-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (320% higher).
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07136012 names 20 study sites across 4 states, led by Alabama, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07136012 about?
NCT07136012 is a clinical study titled "OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events". The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\...
What is the current status of trial NCT07136012?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 11,000 participants. The study started on 2025-08-22. Estimated completion is 2031-10-20.
What conditions does trial NCT07136012 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT07136012?
The interventions under investigation include: Placebo (DRUG), Olpasiran (DRUG).
Who is sponsoring clinical trial NCT07136012?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07136012 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07136012's enrollment target sits among peer trials
11,000 9th of 137 higher than 129 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RECRUITING · Phase 3
-
VITAL Rhythm Study
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
ACTIVE NOT RECRUITING · Phase 3
-
Vitamin D and Omega-3 Trial (VITAL)
ACTIVE NOT RECRUITING · Phase 3
-
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
ACTIVE NOT RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- NCT06736951 · 10,890 participants · NA
Modifying the Inpatient Environment to Reduce Delirium in Older Adults
- NCT06468202 · 10,742 participants · Phase 4
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI